Immix Biopharma closed at $7.97 on Nov 4, up 3.37%, 44.9% below its 52-week closing high. Volume of 1.2M shares was 0.99× its 20-day average (close to normal).
Split-adjusted performance: -17.3% over one month, -22.8% over six months, +119.0% over one year.
Short interest was 10.7M shares at the Oct 15 settlement, up 3.1% from the prior report (22.5% of float, 7.5 days to cover).
No reported quarters with price history yet.
Percentile among 420 companies (100 = best)
Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| IMMXImmix Biopharma | $7.97 | +3.37% | −22.8% | — | — | — | $660.7M | |
| OLMAOlema Pharmaceuticals | $7.54 | +2.58% | −50.4% | — | — | — | $659.7M | Compare |
| LXRXLexicon Pharmaceuticals | $1.48 | +1.37% | −7.5% | −97.6% | −4591.8% | — | $658.5M | Compare |
| ZVRAZevra Therapeutics | $11.17 | +8.87% | −0.7% | +44.9% | 48.8% | 8.6 | $663.3M | Compare |
| AVBPArriVent BioPharma | $13.49 | +3.61% | −54.5% | — | — | — | $665.2M | Compare |
| DSGNDesign Therapeutics | $10.63 | +2.80% | −26.9% | — | — | — | $665.2M | Compare |
| KURAKura Oncology | $7.61 | −22.98% | −20.4% | +36.5% | −327.3% | — | $677.0M | Compare |
| OBXObsidian Therapeutics | $10.99 | −16.93% | — | — | — | — | $678.9M | Compare |
| APMDApnimed | $15.30 | +1.59% | — | — | — | — | $637.0M | Compare |
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
